Top 10 Companies in the (S)-Acetyl-3-mercapto-2-methylpropanoic Acid (CAS 76497-39-7) Market (2026): Market Leaders Powering Global Pharmaceutical Synthesis

MARKET INSIGHTS

The global (S)-Acetyl-3-mercapto-2-methylpropanoic acid (CAS 76497-39-7) market size was valued at USD 48.6 million in 2025. The market is expected to rise from USD 51.2 million in 2026 to USD 84.7 million by 2034, registering a CAGR of 6.5% during the forecast period.

(S)-Acetyl-3-mercapto-2-methylpropanoic acid (CAS 76497-39-7) is a chiral thioester compound widely recognized as a key intermediate in the synthesis of pharmaceutical active ingredients, most notably in the production of Captopril, an angiotensin‑converting enzyme (ACE) inhibitor used in the treatment of hypertension and heart failure. The compound features a protected thiol group in the form of an acetyl group, making it a valuable building block in asymmetric synthesis and fine chemical manufacturing.

The market is witnessing steady growth, propelled by the rising global prevalence of cardiovascular diseases and the sustained demand for Captopril and related ACE inhibitor generics across both developed and emerging economies. Advancements in chiral chemistry and increasing investments in pharmaceutical fine chemicals further reinforce the compound’s relevance in modern drug manufacturing pipelines. Key suppliers and specialty chemical manufacturers operating in this space include companies across China, India, and Europe with established capabilities in chiral intermediate production.

(S)-Acetyl-3-mercapto-2-methylpropanoic acid (CAS 76497-39-7) Market – View in Detailed Research Report

1. Shaanxi Dikang Pharmaceutical Co., Ltd. (China)

Headquarters: Xi’an, China
Key Offering: High‑purity chiral acetyl‑mercaptomethylpropanoic acid and related intermediates for ACE‑inhibitor synthesis.

Shaanxi Dikang has developed a robust asymmetric synthesis route that delivers consistent enantiomeric excess above 98%, meeting the stringent demands of pharmaceutical API production. The company’s state‑of‑the‑art purification processes ensure low impurity profiles in line with ICH Q3A guidelines.

Sustainability & Growth Initiatives:

• Investment in green catalysis to reduce solvent usage.
• Expansion of GMP‑compliant production lines to increase capacity by 30% by 2030.
• Partnerships with major generic manufacturers in Southeast Asia to secure long‑term supply contracts.

2. Sino Compound Pharmaceuticals Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: Custom chiral synthesis services and turnkey production of acetyl‑mercaptomethylpropanoic acid.

Sino Compound’s modular synthesis platform allows rapid scale‑up for both pilot and commercial batches, ensuring quick response to market demand fluctuations. The firm maintains a dedicated quality‑control laboratory that routinely verifies enantiomeric purity and impurity levels.

• Implementation of continuous flow chemistry to enhance yield.
• Collaboration with academic institutions for catalyst development.
• Targeted marketing to emerging generic markets in India and Brazil.

3. Zhejiang Huahai Pharmaceutical Co., Ltd. (China)

Headquarters: Hangzhou, China
Key Offering: Large‑scale production of chiral acetylated thioesters for pharmaceutical intermediates.

With a dedicated chiral purification unit, Zhejiang Huahai consistently delivers product with ee > 99%. The company’s logistics network ensures rapid distribution to key pharmaceutical hubs in Asia.

• Adoption of renewable energy sources in manufacturing.
• Development of a proprietary chiral ligand library.
• Strategic alliances with contract manufacturing organizations (CDMOs) across the EU.

4. Lianhetech (Zhejiang Lianhe Chemical Technology Co., Ltd.) (China)

Headquarters: Zhejiang, China
Key Offering: Specialized chiral synthesis and supply of acetyl‑mercaptomethylpropanoic acid for API development.

Lianhetech’s focus on process optimization has reduced batch cycle times by 15%, enabling faster turnaround for research‑scale projects.

• Investment in automated synthesis platforms.
• Enhanced quality‑management system aligned with GMP standards.
• Partnerships with universities for advanced chiral research.

5. API Corporation (APICORP) (India)

Headquarters: Mumbai, India
Key Offering: Production of high‑purity chiral acetyl‑mercaptomethylpropanoic acid for domestic and export markets.

APICORP’s integrated supply chain, from catalyst sourcing to final product, ensures consistent batch quality and compliance with international regulatory standards.

• Expansion of production capacity to meet growing generic demand.
• Implementation of real‑time analytical monitoring.
• Collaboration with Indian generic manufacturers to secure supply contracts.

6. Aurobindo Pharma Limited (India)

Headquarters: Hyderabad, India
Key Offering: Supply of chiral acetyl‑mercaptomethylpropanoic acid for ACE‑inhibitor synthesis.

Aurobindo’s emphasis on quality assurance and rapid scaling positions it as a preferred partner for large‑volume API production.

• Investment in continuous manufacturing technology.
• Strengthening of quality‑control protocols.
• Strategic procurement of raw materials from regional suppliers.

7. Tokyo Chemical Industry Co., Ltd. (TCI) (Japan)

Headquarters: Tokyo, Japan
Key Offering: Advanced chiral synthesis and purification of acetyl‑mercaptomethylpropanoic acid.

TCI’s precision synthesis processes deliver high enantiomeric purity, meeting the strictest regulatory requirements for pharmaceutical intermediates.

• Research into novel chiral catalysts.
• Enhancement of environmental sustainability in production.
• Collaboration with Japanese generic manufacturers.

8. Combi-Blocks Inc. (United States)

Headquarters: New York, USA
Key Offering: Custom chiral synthesis services and supply of acetyl‑mercaptomethylpropanoic acid.

Combi-Blocks leverages its expertise in chiral chemistry to provide tailored solutions for both research and commercial API production.

• Investment in high‑throughput screening for catalyst development.
• Expansion of service offerings to include analytical support.
• Partnerships with US‑based generic manufacturers.

9. Alfa Chemistry (United States)

Headquarters: Chicago, USA
Key Offering: Supply of high‑purity chiral acetyl‑mercaptomethylpropanoic acid for pharmaceutical intermediates.

Alfa Chemistry’s focus on process efficiency and quality control enables consistent delivery of product that meets global regulatory standards.

• Implementation of lean manufacturing practices.
• Continuous improvement of analytical methods.
• Strategic sourcing of raw materials.

10. Fluorochem Ltd. (United Kingdom)

Headquarters: London, UK
Key Offering: Production of chiral acetyl‑mercaptomethylpropanoic acid and related intermediates.

Fluorochem’s integrated quality management system ensures compliance with GMP and ICH guidelines, positioning it as a reliable supplier for the European market.

• Investment in renewable energy for production.
• Development of eco‑friendly purification processes.
• Collaboration with European generic manufacturers.

Download FREE Sample Report:

Download FREE Sample Report

Get Full Report:

(S)-Acetyl-3-mercapto-2-methylpropanoic acid (CAS 76497-39-7) Market – View in Detailed Research Report

Market Outlook (2026‑2034)

Forecast data indicate a steady upward trajectory, with the market expanding from USD 51.2 million in 2026 to USD 84.7 million by 2034. The compound’s role as a chiral building block for ACE‑inhibitor synthesis, coupled with increasing demand for generics in emerging economies, underpins this growth. The outlook reflects a balanced mix of established pharmaceutical demand and expanding opportunities in bioconjugation and peptide chemistry.

Future Trends and Emerging Opportunities

1. Expansion into Peptide Chemistry and Bioconjugation: The protected thiol functionality is increasingly leveraged for site‑selective conjugation in antibody‑drug conjugates and thiol‑mediated ligation, opening new markets beyond small‑molecule APIs.

2. Localisation of Supply Chains in Emerging Markets: Generic manufacturers in South Asia and Southeast Asia are actively seeking regional suppliers to reduce import dependence, creating demand for locally produced chiral intermediates.

3. Advances in Chiral Catalysis: Ongoing research into asymmetric catalysts promises higher yields and lower environmental impact, potentially reshaping production economics.

4. Academic and Research Demand: Growing investment in fundamental chemistry research sustains a steady, if modest, demand from laboratory reagent distributors.